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A B S T R A C T
Background
Human African trypanosomiasis, or sleeping sickness, is a painful and protracted disease affecting people in the poorest parts of Africa
and is fatal without treatment. Few drugs are currently available for second-stage sleeping sickness, with considerable adverse events
and variable efficacy.
Objectives
To evaluate the effectiveness and safety of drugs for treating second-stage human African trypanosomiasis.
Search methods
We searched the Cochrane Infectious Diseases Group Specialized Register (January 2013), CENTRAL (The Cochrane Library Issue 12
2012) , MEDLINE (1966 to January 2013), EMBASE (1974 to January 2013), LILACS (1982 to January 2013 ), BIOSIS (1926-
January 2013), mRCT (January 2013) and reference lists. We contacted researchers working in the field and organizations.
Selection criteria
Randomized and quasi-randomized controlled trials including adults and children with second-stage HAT, treated with anti-trypanoso-
mal drugs.
Data collection and analysis
Two authors (VL and AK) extracted data and assessed methodological quality; a third author (JS) acted as an arbitrator. Included trials
only reported dichotomous outcomes, and we present these as risk ratio (RR) with 95% confidence intervals (CI).
Main results
Nine trials with 2577 participants, all with Trypansoma brucei gambiense HAT, were included. Seven trials tested currently available
drugs: melarsoprol, eflornithine, nifurtimox, alone or in combination; one trial tested pentamidine, and one trial assessed the addition
of prednisolone to melarsoprol. The frequency of death and number of adverse events were similar between patients treated with fixed
10-day regimens of melarsoprol or 26-days regimens. Melarsoprol monotherapy gave fewer relapses than pentamidine or nifurtimox,
but resulted in more adverse events.
1Chemotherapy for second-stage Human African trypanosomiasis (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Later trials evaluate nifurtimox combined with eflornithine (NECT), showing this gives few relapses and is well tolerated. It also has
practical advantages in reducing the frequency and number of eflornithine slow infusions to twice a day, thus easing the burden on
health personnel and patients.
Authors’ conclusions
Choice of therapy for second stage Gambiense HAT will continue to be determined by what is locally available, but eflornithine and
NECT are likely to replace melarsoprol, with careful parasite resistance monitoring. We need research on reducing adverse effects of
currently used drugs, testing different regimens, and experimental and clinical studies of new compounds, effective for both stages of
the disease.
P L A I N L A N G U A G E S U M M A R Y
Chemotherapy of second-stage Human African trypanosomiasis
Human African trypanosomiasis (HAT), or sleeping sickness, is a painful and protracted disease transmitted through the bite of infected
tsetse flies and it is found in rural parts of sub-Saharan Africa. Sleeping sickness has two clinical phases but this review focuses only on
treatment of the second-stage, which is characterized by neurological changes and almost invariably fatal without treatment. There are
only a few drugs currently available for second-stage sleeping sickness, all with considerable adverse events and variable efficacy.
The review includes nine trials with 2577 participants. Each trial reported different comparisons of the drugs currently available to
treat second stage HAT (melarsoprol, eflornithine, nifurtimox) so no meta-analysis was possible.
Melarsoprol administration is intravenous and very painful, with many adverse reactions including a severe dysfunction of the brain,
that can result in death. For this reason, trials were designed to evaluate shorter melarsoprol regimens. Giving melarsoprol for 10
days was found to be as effective as giving it for 26 days. Recently, nifurtimox and eflornithine combination therapy (NECT) was
assessed. Few patients relapsed after NECT, which was generally well tolerated. It also has practical advantages: eflornithine has to be
administered as a slow intravenous infusion thus requiring specialized health facilities and personnel, but nifurtimox is given orally.
NECT uses less eflornithine doses and reduces the burden on health personnel and patients.
Considering that none of the current therapeutic options for HAT is optimal in terms of adverse events and ease of administration,
it is essential that new anti-trypanosomal compounds are developed and tested in experimental and clinical studies. In the meantime,
local availability of the drugs and the status of health facilities and personnel will dictate choice of treatment. It is envisioned that
melarsoprol, with its high level of adverse events, will be phased out in favour of eflornithine and NECT. The development of parasite
resistance to the drugs needs to be carefully monitored. Future research should also focus on the reduction of the adverse effects of
currently used drugs and better diagnostic tests.
B A C K G R O U N D
Human African trypanosomiasis (HAT), or sleeping sickness, is a
disease caused by the protozoan parasite Trypanosoma brucei that
is transmitted through the bite of infected tsetse flies. The dis-
ease occurs throughout sub-Saharan Africa, wherever tsetse flies
are found. In 2006, it was estimated that 50,000 to 70,000 indi-
viduals were infected (WHO 2006); between 2004 and 2008, the
reported number of new cases was approximately 10,000 (WHO
2009). The eco-distribution of tsetse flies is determined by the
climate, presence of water, vegetation, and their requirement for
blood meals (human or animals), but they are mostly found in ru-
ral and forested areas. Essential human activities such as farming,
collecting water from natural sources, washing, and fishing, can
increase contact between humans and tsetse flies and contribute
to the spread of the disease (Pepin 2001). The incidence of HAT
was reduced to very low levels by the end of the 1950s following
large-scale campaigns of active case detection and surveillance, and
tsetse flies control campaigns (Cattand 2001). However, since the
1960s, the gradual breakdown of control programmes, aggravated
by economic hardship, war, and civil strife in most endemic coun-
tries, resulted in an alarming resurgence of HAT, with epidemics
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in the Democratic Republic of Congo, Angola, Sudan, Uganda,
and the Central African Republic, that resulted in the disruption
of whole communities and with huge socioeconomic costs (Seed
2001). In the past few years the reported number of cases of sleep-
ing sickness has again reduced due to increased control measures,
although the exact number of cases is uncertain because of poor
health services in most of the affected areas (Brun 2010).
Sleeping sickness is a painful and protracted disease which is al-
most invariably fatal without adequate treatment; treatment of in-
fected individuals is crucial for reducing the trypanosome reser-
voir in humans and consequently for controlling the disease. The
mostly rural distribution of the disease, civic unrest occurring in
many regions affected, the financial and social constraints expe-
rienced by endemic countries, and the difficulties in diagnosing
and effectively treating HAT, all contribute to make it one of the
hardest diseases to control in sub-Saharan Africa.
Two subspecies of Trypanosoma brucei can infect humans. T. b.
gambiense causes a generally chronic form of sleeping sickness in
West and Central Africa. T. b. rhodesiense, found in Eastern and
Southern Africa, generally causes a more acute form of the disease.
In both forms the disease is characterized by two clinical stages
related to the propagationof the parasite in the infected host. In the
first stage, when trypanosomes multiply in the haemolymphatic
system, infected individuals experience intermittent episodes of
fever and develop lymphadenopathy, and other non-specific signs
such as hepatosplenomegaly and skin rashes (Stich 2002). In the
second stage of the disease, trypanosomes reach the central nervous
system resulting in a chronic meningoencephalitis with headaches
and extensive neurological changes, which result in severe sleep
disturbances resembling narcolepsy, convulsions, semi-coma, and
death (Stich 2002).
Diagnosis and stage determination of HAT are problematic and
cannot be based on clinical signs alone (Lejon 2005). The presence
of parasites has to be demonstrated in body fluids, and, according
to the World Health Organization (WHO), diagnosis of second-
stageHAT should be based on an examination of the cerebrospinal
fluid (CSF) for trypanosomes, white blood cell (WBC) count of
>5 WBC/µL in CSF, and increased total protein concentration
(WHO 1998; WHO 2004). Patients with up to 5 WBC/µL in
CSF are diagnosedwith first-stageHAT.There is some controversy
about the correct staging of patients with 6 to 20 WBC/µL in
CSF, as many patients in this ’grey zone’ do not display typical
symptoms of second-stage HAT and can be cured with drugs that
do not reach therapeutic levels in the brain (Lejon 2005). AWBC
over 20/µL in CSF has been recommended by an expert panel as a
cut-off point for inclusion of patients in clinical trials for treatment
of second-stage HAT (WHO 2004).
Treatment for both stages of the disease is also complex. Treatment
for the first stage relies on an early diagnosis, often missed due
to the lack of specificity of the initial symptoms, and employs
two drugs (pentamidine for Gambiense HAT and suramin for
Rhodesiense disease) that have been used for more than 60 years
and which can produce severe side effects. However, these drugs
are still effective and in use (Brun 2010). In this review we will
focus on the treatment of second-stage HAT, which is problematic
as drugs available are difficult to administer, and can cause severe
adverse events and even death (Chappuis 2007).
Choice of drugs
Treatment of second-stage HAT relies on melarsoprol, eflor-
nithine, or nifurtimox − at present the only anti-trypanosomal
compounds that can reach therapeutic levels in the central ner-
vous system. These drugs have been in use for many years, and
their in vivo efficacy against HAT has been extrapolated after an-
imal studies or, in the case of nifurtimox, after being used to treat
American trypanosomiasis (Chagas disease). Also, the use of any
of these drugs is complicated by multiple factors including the in-
creasing incidence of therapeutic failures, painful administration,
severe adverse reactions, availability, and high production costs.
Melarsoprol
Melarsoprol, a trivalent organic arsenical compound, has been the
drug of choice for second-stage HAT caused by either T. b. gam-
biense or T. b. rhodesiense since 1949. Melarsoprol is liposoluble
and for this reason can cross the blood brain barrier (Nok 2003);
however, being insoluble in water, it must be administered strictly
intravenously after being dissolved in propylene glycol, which is
highly irritating to tissues. As a result, the administration of melar-
soprol is very painful (Nok 2003). The most appropriate regimen
is not yet agreed upon and various regimens are currently in use.
Melarsoprol causes a variety of adverse reactions, but the most se-
rious is an encephalopathic syndrome. The incidence of this com-
plication varies from 1.5% to 28% of all melarsoprol treatments,
with a median associated fatality rate of 50% (Seixas 2005); be-
cause of this risk, treatment with melarsoprol requires hospitaliza-
tion of the patient (Stich 2003). High rates of therapeutic failure
have been observed in the Democratic Republic of Congo, An-
gola, and Sudan (Legros 2002).
Eflornithine
Eflornithine (difluoromethylornithine, DFMO), an irreversible
inhibitor of ornithine decarboxylase, was developed as an anti-
cancer drug in the 1970s, but it was found insufficiently active for
this indication. Its activity against trypanosomeswas demonstrated
in laboratory animals in 1980. The first HAT patient was treated
in 1981 (with oral eflornithine) and the intravenous formulation
was registered in 1990. Eflornithine is effective against both stages
ofT. b. gambiense infection, but its effectiveness against T. b. rhode-
siense is unreliable because of innate low sensitivity of this parasite.
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Eflornithine is difficult to administer as it requires four daily in-
travenous infusions for seven to 14 days (Burri 2003); recent tri-
als have tested two daily eflornithine doses (Priotto 2009). Eflor-
nithine can induce several adverse reactions such as anaemia, leu-
copenia, pancytopenia, gastroenteric symptoms, headaches, and
sometimes seizures, but it is in general better tolerated than melar-
soprol (Burri 2003). Therapeutic failures with eflornithine in the
second stage of T. b. gambiense disease are uncommon, but relapse
rates of 8.1% were reported (Balasegaram 2006) and need to be
assessed.
Nifurtimox
Nifurtimox was originally developed and registered for use in
American trypanosomiasis and only recently has been reserved for
compassionate use in HATwhen other treatments have failed. Ni-
furtimox has the advantage of being orally active. Both stages of
infection with T. b. gambiense are susceptible to treatment with
nifurtimox, but it has seldom been used as a first-stage drug. Its ef-
ficacy against T. b. rhodesiense has not been assessed (Pepin 1994).
Nifurtimox monotherapy has been used for patients who are re-
fractory tomelarsoprol, with high (75%to85%) cure rates (Moens
1984, Van Nieuwenhove 1992). Adverse effects include dysfunc-
tions of the central nervous system and of the gastrointestinal tract
(Bouteille 2003).
Combination therapies and adjunctive treatments
Combining existing drugs may delay the onset of resistance and
also help reduce dosages and adverse effects (Legros 2002). Com-
bination therapies have been used on a compassionate basis in
patients unresponsive to other drugs. Pre-treatment with first-
stage drugs during second-stage therapy with melarsoprol has fre-
quently been used on an empirical basis to reduce melarsoprol tox-
icity. Combinations of nifurtimox with eflornithine, melarsoprol
with nifurtimox, and nifurtimox and melarsoprol have been tested
(Bouteille 2003); recent trials focusing on nifurtimox-eflornithine
combination therapy (NECT) are reported in this review (Priotto
2009).
Steroids have been used as an adjunctive treatment to melarso-
prol to reduce the frequency of a drug-induced encephalopathy.
Some studies have shown a positive effect of prednisolone co-ad-
ministered with melarsoprol (Pepin 1989a), but the role of corti-
costeroids of different types and at different dosages needs to be
properly assessed.
Future perspectives
No new drugs for treating late-stage sleeping sickness were specif-
ically developed from 1949 until very recently - both nifurtimox
and eflornithine were designed for other indications. The pharma-
ceutical industry has little economic incentive to research and de-
velopnewcompounds for a diseasewith such a limited and unprof-
itable market. Around 2000, manufacturers even seriously con-
sidered abandoning the production of melarsoprol, eflornithine,
suramin, and nifurtimox, and to considerably increase the price of
pentamidine (Stich 2003). Fortunately, inMay 2001, the pharma-
ceutical company Aventis (now Sanofi-Aventis) agreed to guaran-
tee the production of pentamidine, melarsoprol, and eflornithine
for at least five years and to deliver these drugs free of charge to
WHO. The agreement was renewed in 2006 and it is still ongoing.
However, recent research has resulted in the clinical development
of two new compounds, fexinidazole and oxaborole. Fexinidazole
(DNDi 2008) is a 5-nitroimidazole and in experimental studies
was found to be active against both T. b. gambiense and T. b.
rhodesiense, to have a favourable safety profile and to be orally
active. Phase II/III clinical trials of fexinidazole are going to take
place in the Democratic Republic of the Congo, and the Central
African Republic (DNDi 2012). Another oral drug candidate, an
oxaborole-6-carboxamide (SCYX-7158) is undergoing a Phase I
clinical trial (DNDi 2012b).
As progress on the development of new drugs and their clinical
applications is going to take time, the urgent short-term advance
to be made consists of preclinical investigations and of clinical
trials to improve the effectiveness, safety, and ease of administra-
tion of monotherapy regimens using melarsoprol, eflornithine, or
nifurtimox, and, most importantly, of regimens with combina-
tions of these drugs. A multicentre NECT trial run by Medecines
sans Frontieres, Epicentre, Drugs for Neglected Diseases Initiative
(DNDi), and the Swiss Tropical institute, in collaboration with
national Ministries of Health and HAT programs, has recently
ended. On the basis of its results, a proposal for the inclusion of
the combination of eflornithine and nifurtimox as treatment for
second-stage sleeping sickness in the WHOmodel list of essential
medicines (EML) was submitted inNovember 2008 and approved
in May 2009 (WHO 2010).
Our review aims to examinewhether any of the current drugs, their
combinations, or their combinations with adjunctive treatments
at any particular dosage provides a definite advantage over other
regimens for the treatment of second-stage HAT, measured in
terms of clinical outcomes and in relation to the severity of adverse
effects.
O B J E C T I V E S
Toevaluate the effectiveness and safety of drugs for treating second-
stage HAT.
M E T H O D S
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Criteria for considering studies for this review
Types of studies
Randomized and quasi-randomized controlled trials.
Types of participants
• Adults and children with a primary diagnosis of second-
stage HAT, that is, having evidence of trypanosomal infection
and a CSF analysis showing a WBC count of more than 5 cells/
µL, with no upper limit, and/or the presence of trypanosomes.
• Adults and children relapsing after treatment for second-
stage HAT.
Types of interventions
Intervention
Drugs for treating HAT, including melarsoprol, eflornithine, and
nifurtimox. Drugs may be given alone, in combination (concomi-
tantly or sequentially), or with an adjunctive treatment.
Control
Other drugs for treating HAT or different regimens of the inter-
vention drugs (eg different dose, frequency, or route of adminis-
tration).
Types of outcome measures
Primary
• Death during treatment, up to one month after the last
drug administration.
• Overall mortality (for any reason, including HAT and
treatment toxicity) up to one month after the last drug
administration.
• Relapse during follow up: trypanosomes detected in any
body compartment (blood, lymph, or CSF) at any follow-up
examination (between one and 24 months after the last drug
administration); or CSF leukocyte count > 50 WBC/µL CSF, or
doubled from previous count, at any follow-up examination; or
CSF leukocyte count between 20 and 49 WBC/µL CSF
together with symptoms strongly suggestive of relapse (worsened
clinical condition since previous examination, with long lasting
headache, mental and/or neurological disturbances, increased
somnolence, recurrent fever, etc).
Secondary
• Death likely to be due to HAT, up to one month after the
last drug administration.
• Relapse: trypanosomes detected in any body compartment
(blood, lymph, or CSF) up to one month after the last drug
administration.
Adverse events
• Central nervous system adverse events: encephalopathy,
seizures, confusion.
• Bone marrow toxicity: anaemia, leucopenia,
thrombocytopenia.
• Gastrointestinal symptoms: diarrhoea, nausea and vomit.
• Skin reactions
• Infections
• Cardiotoxicity.
Search methods for identification of studies
We attempted to identify all relevant trials regardless of language
or publication status (published, unpublished, in press, and in
progress).
Databases
We searched the following databases using the search terms and
strategy described in Appendix 1: Cochrane Infectious Diseases
Group Specialized Register (January 2013); Cochrane Central
Register of Controlled Trials (CENTRAL), published in The
Cochrane Library 2012, Issue 12; MEDLINE (1966 to January
2013); EMBASE (1974 to January 2013) ; LILACS (1982 to Jan-
uary 2013); and BIOSIS (1926-January 2013) . We also searched
themetaRegister of Controlled Trials (mRCT, accessed 11 January
2013) using trypanosom* as the search term.
Conference proceedings
We searched the conference proceedings of The International Sci-
entific Council for Trypanosomiasis Research and Control (ISC-
TRC) Conferences for relevant abstracts.
Researchers, organizations, and pharmaceutical
companies
We attempted to locate unpublished and ongoing trials by con-
tacting individual researchers working in the field; organizations
including Médecins sans Frontières, Epicentre, Malteser, WHO,
and TDR.
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Data collection and analysis
Selection of studies
All trials identified through systematic literature searches were en-
tered into a database that was screened independently by VL and
JS for potentially relevant trials. VL retrieved the full articles of the
potentially relevant trials. The three authors together applied the
inclusion criteria on the potentially relevant trials using an eligibil-
ity form and prepared lists of included and excluded studies. We
described the reasons for excluding studies in the ’Characteristics
of excluded studies’.
Data extraction and management
VL and AK independently extracted data from the included stud-
ies using standardized data extraction forms. JS compared the two
data extraction form and prepared a final version. VL entered the
data into Review Manager 5. We extracted the number of partic-
ipants randomized and analysed in each group. For each dichoto-
mous outcome measured, we recorded the number of participants
experiencing the event and the number analysed in each group.
Assessment of risk of bias in included studies
VL and AK independently assessed the methodological quality of
the included trials using a standardized form. We assessed gener-
ation of randomization sequence, allocation concealment, blind-
ing, and loss to follow up. We categorized the generation of al-
location sequence and concealment to be adequate, inadequate,
or unclear according to Jüni 2001. We assessed which party was
blinded in each trial (study investigators, participants, or study as-
sessors). We considered inclusion of 90% or more of the random-
ized participants in the analysis to be adequate, and less than 90%
to be inadequate. Disagreements were resolved by discussion or by
reassessment of the data extraction forms by JS.We also attempted
to contact the trial authors for any information not specified or
unclear.
Data synthesis
VL analysed data using ReviewManager 5. Included trials only re-
ported dichotomous outcomes. We did not perform a meta-anal-
ysis. Results were presented in forest plots and tables and analysis
were stratified by comparisons and by doses/regimens of the drugs.
Measure of effect
We presented outcomes for dichotomous data as risk ratio (RR)
with 95% confidence intervals (CI).
Dealing with missing data
We analysed data extracted from the trials on an intention-to-treat
basis when there were no missing data, or we used a complete-case
analysis, using the number of participants for whom outcomes
were reported.
R E S U L T S
Description of studies
Our first search in May 2010 identified 25 potentially eligible
trials. Sixteen trials were excluded (see ’Characteristics of excluded
studies’) and nine met the inclusion criteria (see ’Characteristics
of included studies’).
A second search, for the updated version of this review in January
2013, identified no newly published RCTs but resulted in 2 on-
going trials of interest (DNDi 2012 and DNDi 2012b).
Trial location and participants
All included trials were conducted in one of the following coun-
tries: Democratic republic of Congo, Republic of Congo, Angola,
Uganda, Cote d’Ivoire. Two multicenter trials (Pepin 2000 and
.Priotto 2009 had sites in different countries. Eight trials were
conducted in hospitals or specialized trypanosomiasis units, in one
(Lejon 2003) the setting was unspecified. The oldest included trial
is Pepin 1989a.
Four trials (Bisser 2007, Burri 2000, Pepin 2006, Priotto 2009)
did not include young children but only adolescents and adults.
One trial (Na-Bangchang 2004) only included adults (over 18
years), the remaining four trials (Lejon 2003, Pepin 1989a, Pepin
2006, Priotto 2006) included both adults and young children.
Five trials (Bisser 2007, Burri 2000, Na-Bangchang 2004, Pepin
2000, Priotto 2006) excluded pregnant patients. Except for Lejon
2003, Pepin 1989a and Priotto 2006, the remaining six trials ex-
cluded severely ill patients, defined either as in a “moribund con-
dition”, with “severe organ disease”, “severe comorbidities” or in
unarousable coma (Glasgow Coma score ≤ 8).
The total number of participants randomized in the included trials
was 2577. All included patients suffered fromT. b. gambienseHAT
as we did not identify any RCT describing treatment for T. b.
rhodesiense. Five trials (Bisser 2007, Pepin 2006, Priotto 2006,
Priotto 2009) did not include participants that had a history of
treatment for sleeping sickness (at any time or during the last 36
months), but three trials (Burri 2000, Lejon 2003, Pepin 1989a)
did not mention this characteristic and Pepin 2000 included both
new and relapsing cases.
Interventions
Seven trials tested the effectiveness of the currently available drugs
to treat second stage HAT: melarsoprol, eflornithine, nifurtimox,
used alone or in combination. Lejon 2003 tested the effectiveness
of pentamidine, which is indicated to treat first stage HAT, in
patients showing a CSFWBC count between 6 and 20WBC/µL.
Pepin 1989a tested melarsoprol with or without prednisolone as
an adjunctive treatment to reduce the frequency of melarsoprol-
induced encephalopathy.
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Two trials (Burri 2000 and Pepin 2006) compared different regi-
mens of melarsoprol. Two trials (Na-Bangchang 2004 and Pepin
2000) tested different regimens of eflornithine.
One trial (Bisser 2007) included comparisons between three
monotherapies (two different regimens of melarsoprol, or nifur-
timox alone) and a melarsoprol-nifurtimox combination.
Priotto 2006 reports on comparisons between dual combinations
of melarsoprol, eflornithine and nifurtimox; Priotto 2009 com-
pares eflornithine monotherapy given for 14 days, with an eflor-
nithine-nifurtimox combination given for seven days.
Additional treatments
It is common practice to pre-treat HAT patients against other dis-
eases which are endemic in the same areas, such as malaria and
helminthiasis. HAT patients are often treated with prednisolone
to reduce the risk of melarsoprol-induced encephalopathy, and in
some of the included trials they received multivitamins, paraceta-
mol or food rations (also given to their accompanying carers as
hospitals and health centres in the endemic areas don’t usually have
enough resources to provide food). We have listed the details of
the additional treatments for each trials in a separate table (Table
1).
Dosing and regimens
Melarsoprol monotherapy
Melarsoprol was always used intravenously; dosages and schedules
tested varied between studies. A “standard regimen” (three series
of 3.6 mg/kg/day for three days, with a seven day break between
series for a total duration of 26 days) was used in Bisser 2007 and
Pepin 2006. A shorter schedule of melarsoprol at 2.2 mg/kg/day
for 10dayswas used byBurri 2000, in comparisonwith a “standard
Angolan schedule” over 26 days as follows: 1.2 mg/kg on day one,
2.4 mg/kg on day two, 3.6 mg/kg on day three and four, repeated
on days 12-15 and 23-26. A 10 day schedule of melarsoprol at
2.16 mg/kg/day was used by Pepin 2006. Incremental melarsoprol
was also used by Bisser 2007 at doses from 0.6 mg/kg to 1.8 mg/
kg for the first three days, followed by the same dose of 1.8 mg/kg/
day until day 10, and by Pepin 2006 where the doses started at 1.8
mg/kg up to 3.6mg/kg for three series of three injections separated
by seven days. Pepin 1989a used a 3.6 mg/kg dose of melarsoprol
but the number of series and injections varied according to the
white blood cell count of the patient - this is known as a Neujean
schedule.
Nifurtimox monotherapy
Nifurtimox was administered orally at 5 mg/kg every eight hours
for 10 days in Bisser 2007.
Eflornithine monotherapy
Oral eflornithine was tested in Na-Bangchang 2004 comparing
doses of 400 mg/kg/day with 500 mg/kg/day. Pepin 2000 com-
pared intravenous eflornithine (which is given a slow infusion) at
400 mg/kg/day for seven compared with 14 days in a trial includ-
ing new and relapsing patients. Priotto 2009 tested eflornithine
only given a slow infusion at 400 mg/kg/day for 14 days against
the combination of nifurtimox-eflornithine described below.
Pentamidine monotherapy
Pentamidine was used in Lejon 2003 at a dose of 4 mg/kg for 10
days, given intramuscularly, for patients in the so-called interme-
diate stage (ie with a CSF cell count between 6 and 20 cells/µL).
Combination therapies
1) Melarsoprol-nifurtimox low-dose combination (Bisser 2007)
for 10 days: melarsoprol alone at 0.6 mg/kg intravenously on day
one and at 1.2 mg/kg intravenously on day two, followed by eight
days of oral nifurtimox at 7.5mg/kg every twelve hours, combined
with melarsoprol at 1.2 mg/kg intravenously/day.
2) Melarsoprol-nifurtimox was used in Priotto 2006 at doses of
1.8 mg/kg/day intravenous melarsoprol for 10 days, and oral ni-
furtimox at 15 mg/kg/day every eight hours for 10 days.
3) Melarsoprol-eflornithine (intravenous melarsoprol , eflor-
nithine as slow infusion) was used in Priotto 2006: melarsoprol at
1.8 mg/kg/day for 10 days, eflornithine at 400 mg/kg/day, every
six hours for seven days.
4) Melarsoprol + prednisolone (Pepin 1989a) added oral pred-
nisolone at 1 mg/kg/day, given at intervals, to a Neujean schedule
of melarsoprol.
5)Nifurtimox-eflornithine was used in Priotto 2006 and in Priotto
2009 as oral nifurtimox at 15 mg/kg/day every eight hours for 10
days, added to eflornithine as a slow infusion at 400 mg/kg/day,
every six hours for 7 days (Priotto 2006) or every 12 hours for
seven days (Priotto 2009).
Outcome measures
The included trials measured different outcomes from our pro-
tocol: most trials did not differentiate between death due to the
disease or due to treatment (encephalopathy caused by melarso-
prol), and measured death related to treatment or within 30 days
of ending it. Parasitological cure rates (trypanosomes in any body
compartment) weremeasured usually within one day from the end
of treatment.
Follow-up was done at several time points, up to 24 months for
all trials except Na-Bangchang 2004 (12 months), Pepin 1989a
(36 months), and Priotto 2009 (18 months). Outcomes measured
at any follow-up point included trypanosomes in any body com-
partment, an increase in WBC in CSF more than 50 cells/µL or a
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lower increase (20 to 49 cells/µL) together with symptoms typical
of relapse. We grouped these outcomes as “relapse during follow-
up”.
Adverse events
Adverse events represent one of the major measurable outcomes
during sleeping sickness treatment, especially in trials which use
melarsoprol which can cause severe encephalopathies.
All trials except Lejon 2003 reported in detail on several adverse
events, (although different trials did not report exactly the same
adverse events): central nervous system (CNS) alterations, gas-
trointestinal symptoms such as diarrhoea and abdominal pain,
cardiac arrhythmia, leukopenia, neutropenia, infections, and skin
reactions.
Risk of bias in included studies
We included nine randomized controlled trials. See ’
Characteristics of included studies’ for details, also Figure 1 and
Figure 2.
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Figure 1. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
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Figure 2. Methodological quality graph: review authors’ judgements about each methodological quality
item presented as percentages across all included studies.
Generation of allocation sequence and concealment
Five trials reported block randomization. Four trials (Bisser 2007,
Burri 2000, Priotto 2006 and Priotto 2009 ) reported computer-
generated randomization sequences, three trials did not describe
how the participants were randomized, one reported that random-
ization was done in hospital without describing the methods used
(Pepin 2000).
Four trials (Bisser 2007, Burri 2000, Priotto 2006 and Priotto
2009) reported using sealed, opaque envelopes to conceal alloca-
tion sequence. In two trials (Pepin 2000, Pepin 2006) allocation
concealment was not attempted, the other trials did not report on
it.
Blinding
Blinding of participants or clinical teamswas not feasible inmost of
the included trials, because regimens and modes of administration
of the drugs compared were too different to allow it. Only one
trial mentioned that the assessors of clinical results were blinded
(Burri 2000) and one trial (Lejon 2003) reported that the clinical
team was blinded.
Inclusion of randomized participants
Five trials reported rates of follow-up that were greater than 90%
(Bisser 2007, Lejon 2003, Na-Bangchang 2004, Priotto 2006,
Priotto 2009). Two trials had follow-up rates of less than 90 %
- Burri 2000 at 88.4% and Pepin 2000 with 76.6%. For the re-
maining two trials it was not clear how many participants were
lost to follow-up, although from Pepin 1989a one could conclude
that there was no loss to follow up. Numbers of losses to follow-
up are not mentioned in Pepin 2006 where, however, one of the
three arms of the trial had to be stopped because of adverse events.
Effects of interventions
All adverse events described below are also listed in Table 2.
1. Melarsoprol monotherapy: dosages and regimens
1.1. Graded 26 days (Angolan schedule) versus fixed 10 days
Burri 2000 compared these regimens in two groups of 250 par-
ticipants. There were no significant difference between the groups
death during treatment (six in each group; Analysis 1.1), but the
overall mortality was higher in the Angolan scheme: 12 versus 9;
RR 1.33, 95% CI 0.57 to 3.11. The same number of participants
in both groups (14/250) developed encephalopathy and there were
nodifferences in the number of diarrhoea cases in the twogroups of
participants (17 and 18 respectively; Table 2). Participants treated
for 10 days experienced a higher number of skin reactions (39/
250 versus 15/250 for the 26 days schedule; Table 2). Number of
relapses during follow up were higher in the Angolan scheme (5
versus 3) but not significantly different (RR1.67, 95% CI 0.40 to
6.90 Analysis 1.3)
1.2. Standard (3.6 mg) versus graded 26 days
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In Pepin 2006 a standard dose of melarsoprol was compared to
a graded dose, both given for 26 days. The group of participants
receiving the standard dose had a lower risk of death during treat-
ment (RR 0.47, 95% CI 0.12 to 1.82; Analysis 1.1) and a lower
number of seizures (7/149 compared to 7/70 for graded melar-
soprol). As the clinical team was not blinded, enrolment in the
graded melarsoprol arm was stopped early.
1.3. Standard (3.6 mg) versus incremental 10 days
Bisser 2007 found higher overall mortality (9/70) in the group that
received incremental melarsoprol for 10 days than in the group
of patients treated with standard melarsoprol (5/69, Analysis 1.2).
The risk of relapse during follow-up was lower in the standard
melarsoprol group (RR 0.42, 95% CI 0.18 to 0.94; Analysis 1.3).
Numbers of participants suffering encephalopathy, diarrhoea, nau-
sea and vomiting were similar in the two groups but the longer
standards schedule resulted in more phlebitis 19/69 versus 13/70
(see Table 2).
1.4. Standard melarsoprol (3.6 mg) versus fixed 10 days
Pepin 2006 evaluated the effectiveness of a standard dose of melar-
soprol given over 26 days compared with a shorter regimen of 10
consecutive daily injections, finding that the frequency of death
during treatment did not vary significantly (4/149 for the stan-
dard dose versus 6/170 for the 10 days regimen, Analysis 1.1).
The number of neurological adverse events (seizures, confusion)
was also similar in the groups (see Table 2) but the group receiving
a shorter schedule had more skin reactions (6/170 versus only 1/
149 in the standard melarsoprol group).
1.5. Graded 26 days versus fixed 10 days
Pepin 2006 reported that the frequency of death during treatment
was not significantly different between groups receiving the two
treatments (Analysis 1.1). Seizures were more frequent in the par-
ticipants receiving graded melarsoprol (7/70) than in those receiv-
ing the fixed 10-day schedule (4/170). Skin reactions were expe-
rienced with the shorter schedule (6/170).
2. Eflornithine monotherapy: dosages and regimens
Different regimens for eflornithine monotherapy were tested in
two trials.
Pepin 2000 compared the same dose of 400 mg/kg/day, given as a
slow intravenous infusion every six hours, for seven or 14 days, in
groups of patients recruited from four different sites. Participants
treated for seven days had lower risk of death during treatment
(RR0.21, 95%CI 0.02 to 1.75) than those on the 14-day schedule
(Analysis 2.1), and fewer of them suffered gastrointestinal symp-
toms (Table 2), but the shorter schedule resulted in more relapses
during follow up (28/158 against 14/163; RR 2.06, 95% CI 1.13
to 3.77 Analysis 2.3).
Na-Bangchang 2004 used eflornithine orally, as this may consti-
tute a more convenient way of administration than the slow intra-
venous infusion, and compared two doses of 500 and 400 mg/kg/
day in two small groups of participants (13 and 12).There were
no deaths in the two groups, and rates of relapse (Analysis 2.3)
and adverse events (diarrhoea, anaemia, leukopenia) were similar.
3. Comparisons between single drugs
(monotherapies)
3.1. Melarsoprol (standard 3.6 mg) versus nifurtimox (14
days)
This comparison was tested by Bisser 2007. The frequency of
death during treatment or overall mortality was not significantly
different in the two groups (Analysis 3.1 and Analysis 3.2), but
patients receiving melarsoprol had fewer relapses during follow up
(RR 0.30, 95% CI 0.14 to 0.64; Analysis 3.3). Encephalopathy
was more frequent in the melarsoprol group (4/69 participants)
than in the nifurtimox group (1/70), and experienced a high num-
ber of infections (phlebitis; 19/69), but participants receiving ni-
furtimox had more gastrointestinal symptoms such as nausea and
vomiting.
3.2. Melarsoprol (incremental 10 days) versus nifurtimox (14
days)
This comparison was tested in Bisser 2007 in two groups of 70
participants each. There was no difference in the number of deaths
during treatment (three in each group), but the overall mortality
was much lower in the nifurtimox group - three versus nine (RR
0.33, 95% CI 0.09 to 1.18; Analysis 3.2), while the number of
relapses was higher in participants who has received nifurtimox
(24/70) than in those treated with melarsoprol (17/70; Analysis
3.3). Participants in the melarsoprol group had a high number of
phlebitis (13/70; Table 2).
3.3. Melarsoprol (standard (graded)) versus pentamidine
Lejon 2003 compared melarsoprol with pentamidine, which is
more commonly used for first stage HAT, in participants with
20 or fewer cells in CSF. The only reported outcome is relapse,
which was more frequent in participants treated with pentamidine
(Analysis 3.4). No adverse events were recorded.
4. Combination therapies
4.1. Melarsoprol versus melarsoprol + prednisolone
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In Pepin 1989a, a Neujean schedule of melarsoprol was compared
to the same schedule with added oral prednisolone. The differ-
ences in the number of deaths and relapses in the two groups
were not statistically significant (Analysis 4.2 and Analysis 4.4),
but participants who receivedmelarsoprol only had amuch higher
number of encephalopathies (35/308) compared with those who
also received prednisolone (12/290; Table 2).
4.2. Melarsoprol (standard 3.6 mg) versus melarsoprol-
nifurtimox (10 days)
There was no statistically significant difference in the number of
deaths between the two groups of 69 participants each, but partic-
ipants treated with melarsoprol-nifurtimox had no relapses com-
pared with seven occurring in the melarsoprol group (RR 0.07,
95%CI0.00 to 1.15; Analysis 4.4) lower numbers of encephalopa-
thy cases (2/69 versus 4/69 for standard melarsoprol), and lower
numbers of phlebitis (6/69 versus 19/69; Table 2).
4.3. Melarsoprol (incremental 10 days) versus melarsoprol-
nifurtimox
Bisser 2007 reported no relapses in the group of participants who
received the combinationofmelarsoprol andnifurtimox (RR0.03,
95% CI 0.00 to 0.47; Analysis 4.4); differences in the number of
deaths during treatmentwere not significant (Analysis 4.2).Melar-
soprol-nifurtimox also reduced the number of encephalopathies
(2/69 versus 5/70), and of phlebitis (6/69 versus 13/70; Table 2)
but the two groups had similar numbers of gastrointestinal symp-
toms.
4.4. Nifurtimox (14 days) versus melarsoprol-nifurtimox
Melarsoprol-nifurtimox was compared to nifurtimox monother-
apy in Bisser 2007: there were no relapses in the 69 participants
receiving the drug combination (RR 0.02, 95% CI 0.00 to 0.33;
Analysis 4.4). Overall mortality was higher in the melarsoprol-ni-
furtimox group of participants (6/69 versus 3/70 deaths; Analysis
4.3), who also reported two cases of encephalopathy against only
one case in the nifurtimox group, and six cases of phlebitis (Table
2). Participants treated with nifurtimox alone had slightly more
nausea and vomiting (Table 2).
4.5. Eflornithine versus eflornithine-nifurtimox
Priotto 2009 compared eflornithine monotherapy given every six
hours for 14 days, with a eflornithine-nifurtimox combination
(eflornithine given every 12 hrs for seven days + oral nifurtimox
for 10 days). The results (Analysis 4.2; Analysis 4.3; Analysis 4.4)
show that although number of deaths were similar, there were
more relapses during follow-up in the eflornithine group. Partici-
pants treated with eflornithine-nifurtimox had more seizures (18/
143) than those receiving eflornithine only (13/143), and also
experienced more nausea and vomiting (69/143 versus 29/143),
but they did not experience diarrhoea and also had fewer cases
of neutropenia (2/143 versus 10/143). Eflornithine caused more
infections and more skin reactions when used alone than when
combined with nifurtimox (Table 2).
4.6. Eflornithine-nifurtimox versus melarsoprol-eflornithine
Priotto 2006 evaluated this comparison in two relatively small
groups of participants (17 and 19 respectively). There were sig-
nificantly fewer deaths in the group treated with eflornithine-ni-
furtimox (RR 0.37, 95% CI 0.02 to 8.53 for deaths during treat-
ment; (Analysis 4.2); RR 0.37, 95% CI 0.04 to 3.25 for over-
all mortality, (Analysis 4.3). The risk of relapse during follow up
was significantly smaller for participants treated with eflornithine-
nifurtimox (RR 0.28, 95% CI 0.03 to 2.26,( Analysis 4.4). The
eflornithine-nifurtimox group reported more seizures (4/17) and
more participants developed neutropenia (3/17) than in themelar-
soprol-eflornithine group; however the latter had more gastroin-
testinal symptoms (see Table 2).
4.7. Eflornithine-nifurtimox versus melarsoprol-nifurtimox
There was a significant lower risk of death during treatment (RR
0.12, 95% CI 0.01 to 2.03, Analysis 4.2), overall mortality (RR
0.15, 95% CI 0.02 to 1.10, Analysis 4.3), and relapse during
follow up (RR 0.11, 95% CI 0.02 to 0.74, Analysis 4.4) in the
group of participants treated with eflornithine-nifurtimox. The
two groups reported similar number of adverse events (seizures,
gastrointestinal symptoms; Table 2), but more eflornithine-nifur-
timox participants developed neutropenia (3/17 versus 0/18).
4.8. Melarsoprol-eflornithine versus melarsoprol-nifurtimox
There were fewer deaths during treatment (RR 0.24, 95%CI 0.03
to 1.92, Analysis 4.2), less overall mortality (RR 0.41, 95% CI
1.12 to 1.33, Analysis 4.3), and fewer relapses (RR 0.38, 95% CI
0.14 to 0.99, Analysis 4.4) in the group that received melarso-
prol-eflornithine. Twice as many participants in the melarsoprol-
nifurtimox group had seizures (4/18) but fewer developed diar-
rhoea, nausea, and vomiting than those treated with melarsoprol-
eflornithine (Table 2). Only one participant in the melarsoprol-
eflornithine group suffered neutropenia.
D I S C U S S I O N
This review’s objectives were to assess the effectiveness and safety of
drugs used for treating second-stage human African trypanosomi-
asis. All the trials we identified refer to treatment for HAT caused
by T. b. gambiense; we did not find any RCT reporting on treat-
ment for HAT caused by T.b. rhodesiense. Trials on treatment of T.
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b. rhodesiense would have been analysed and discussed separately
from the T. b. gambiense trials and will be included, if available, in
future updates of the review.
Trials of treatment for sleeping sickness encounter logistic, orga-
nizational and clinical difficulties that have to be taken into con-
sideration when assessing trial design and methodological quality.
The number of drugs available is very limited, routes of admin-
istration are painful or difficult to secure under field conditions,
and toxicity high. Also, the quantity of drugs available may be a
limiting factor under field circumstances, and clinical trials may
have to be interrupted because of local political instability. Drug
regimens were mainly empirically developed and scarce pharma-
cokinetic data are available. Pharmaceutical companies have lit-
tle commercial interest in developing new drugs for HAT. For all
these reasons, efforts have been focused on optimizing and min-
imizing drug regimens and reducing adverse events. We grouped
the treatments tested in the included randomized controlled trials
as drug monotherapies (melarsoprol regimens, eflornithine regi-
mens), comparisons between monotherapies and in more recent
trials, comparisons of several drug combinations. No meta-analy-
sis was possible as no two trials compared the same treatment.
Some aspects of the methodological quality of most trials were not
optimal, but this was related to the characteristics of the treatment
under investigations. The different routes of administration and
regimes under comparison would not have allowed blinding of
participants and medical personnel in any of the trials. Allocation
concealment and randomization methods however were adequate
and well described in most trials. Furthermore, the priority in the
past was mainly to treat the enormous existing number of patients
in order to be able to control the disease; we did not include studies
which were not randomized, but many of these excluded publi-
cations reported on important medical observations. This applies
in particular to T. b. rhodesiense second-stage disease in which no
randomized controlled trials were found. Rhodesiense HAT tends
to occur in self-limited epidemic outbreaks or as isolated cases,
and the reported cases represent less than 10% of all HAT cases
(Simarro 2008).
1) Monotherapies - melarsoprol and eflornithine
Melarsoprol can induce a life-threatening encephalopathy in a
large percentage of treated patients (Seixas 2005) and trials assess-
ing melarsoprol have been aimed at minimizing doses of the drug
and length of treatment while maintaining anti-trypanosome ac-
tivity.
Fixed 10-day regimens were found to be as effective as those of 26
days and resulted in similar levels of adverse events (Burri 2000 and
Pepin 2006). They offer however significant practical advantages
(fewer painful injections, less drug used and shorter treatment
duration). Slightly different graded 26-day melarsoprol regimens
were used in Burri 2000 and Pepin 2006, and an incremental
10-day regimen was tested in Bisser 2007. Although Burri 2000
did not report differences in outcomes or adverse events between
the graded schedule and the 10-day schedule, the other two trials
showed that graded or incremental melarsoprol resulted in higher
death rates, higher number of seizures (Pepin 2006) and more
relapses (Bisser 2007), suggesting that incremental melarsoprol
schedules should be abandoned (Pepin 2006).
A large multinational non-randomized clinical study (Schmid
2005) also confirmed the effectiveness (non-inferiority) of the
shorter 10-day melarsoprol schedule, in comparison with the stan-
dard 26 days of treatment, with regard to cure rates and ad-
verse events. The applicability of this abridged 10-day melarsoprol
schedule to Rhodesiense HAT patients has recently been tested
in a utilization study in two trial centres in Uganda an Tanzania
(IMPAMEL IIII), showing similar levels of adverse events with
historical controls. The potential implementation of this abridged
melarsoprol schedule to second stage Rhodesiense HAT patients is
currently being evaluated, but the trial was non-randomized and
outside the inclusion criteria of this review.
Pepin 1989a showed that the addition of prednisolone to melar-
soprol reduced the number of encephalopathy cases and associ-
ated mortality. Prednisolone and other corticosteroids had been
used as an adjunctive treatment to melarsoprol for many years
but this was the first randomized trial to test it and indicate its
effectiveness. This trial is however of insufficient methodological
quality (Figure 1). Prednisolone and prednisone are currently still
in use in patients receiving melarsoprol as no suitable alternative
encephalopathic syndrome preventive treatment has been identi-
fied, but their effectiveness remains unclear.
Eflornithine is effective against T. b. gambiense and induces less se-
vere adverse events than melarsoprol, but it has to be administered
as a slow intravenous infusion every six hours and this is difficult
under field conditions. Pepin 2000 tested a 7-day against a 14-day
regimen and showed that treating for seven days resulted in fewer
deaths and fewer adverse events in patients relapsing from a previ-
ous episode of sleeping sickness, making it a suitable alternative in
this kind of patient. The 7-day regimen was however less effective
than the 14-day schedule especially for new cases. Na-Bangchang
2004 tested oral eflornithine at two slightly different dosages (500
and 400 mg/kg/day). There were no deaths in this trial, and sim-
ilar levels of adverse events between the two patient groups, but
oral eflornithine seemed not to reach adequate levels in plasma
and CSF, and further development of this administration route
was abandoned.
3) Comparisons between single drugs
Bisser 2007 tested two melarsoprol regimens, a standard 26-day
regimen and an incremental 10-day regimen, against nifurtimox.
The two melarsoprol regimens were more effective at preventing
relapses than nifurtimox alone, but induced more cases of en-
cephalopathies, and overall mortality was highest with incremen-
tal melarsoprol.
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Melarsoprol also gave fewer relapses than pentamidine (Lejon
2003) but no other outcomes or adverse events were reported in
this trial. The results of this trial indicate that the use of pentami-
dine (commonly used for first stage HAT) in patients in the so-
called intermediate stage is hazardous and that better markers of
disease stage are needed to allow its safe use in this clinical situa-
tion.
4) Combination therapies
Since 2006, two-drugs combinations between any of the drugs
used in second-stage HAT (melarsoprol, eflornithine and nifur-
timox) have been tested in randomized controlled trials.
Bisser 2007 tested a combination of melarsoprol and nifurtimox,
given for 10 days, against standard or incremental melarsoprol
regimens, and against nifurtimox alone, in an equivalence trial.
Melasorprol-nifurtimox was more effective thanmonotherapies at
reducing the number of relapses but adverse events were compa-
rable between groups and encephalopathies were reported in all
regimens which included melarsoprol.
A trial testing comparing melarsoprol-nifurtimox with melar-
soprol-eflornithine and nifurtimox-eflornithine had to be inter-
rupted because of the high number of deaths, due to reactive
encephalopathy, reported in the melarsoprol-nifurtimox group
(Priotto 2006). The same trial showed that patients receiving ni-
furtimox-eflornithine had a lower risk of relapse and fewer deaths
than those receiving drug combinations with melarsoprol. Follow-
ing this initial observation amuch largermulti-site trial to compare
eflornithine with nifurtimox-eflornithine (thus completely remov-
ingmelarsoprol)was planned, implemented in selectedHATtreat-
ment centres and recently completed (Priotto 2009). The com-
bination of nifurtimox and eflornithine (NECT) was shown to
give fewer relapses and was generally well tolerated. A satisfactory
safety profile of NECTwas confirmed in a non-randomized study
in the Democratic Republic of Congo, which included children
and pregnant women (Schmid 2012), and in a recent cohort study
(Alirol 2013) which also included children . A major advantage
of NECT is the reduction in the frequency and number of eflor-
nithine slow infusions to twice a day, thus reducing the burden on
health personnel and patients alike. Priotto 2009 was designed as
a non-inferiority trial and its clinical results confirmed the non-
inferiority ofNECT to eflornithine alone; other considerations are
the practical advantages of using NECT in terms of drug quanti-
ties, personnel time and logistic costs. Furthermore, the combined
use of two drugs should decrease the emergence of resistance.
Future perspectives
NECT was approved by the Expert Committee on the Selection
and Use of Essential Medicines at its 17th meeting on 30 April
2009 andwas included in theWHOEssential List ofMedicines for
the treatment of human African trypanosomiasis (WHO 2010).
Treating second-stage HAT patients without the need for melar-
soprol has the clear advantage of removing the risk of encephalo-
pathic syndromes and other severe adverse events. NECT has this
and other significant advantages in comparison with other thera-
pies, but it still requires two drugs, used for several days, involving
specialized health personnel. Further refinements and reductions
of this combination need to be tested, and additional field studies
as well as the establishment of an appropriate dose regimen for
NECT in children are planned (DNDi 2008).
The development of new (and easier to use) drugs would represent
a big step forward for the management of second-stage HAT. A
promising recent initiative is the announcement by DNDi that
fexinidazole is entering clinical development for HAT and that
an agreement was signed with Sanofi-Aventis for its further devel-
opment. Fexinidazole is a 5-nitroimidazole and in experimental
studies was found to be active against both T. b. gambiense and T.
b. rhodesiense. Phase II studies of oral fexinidazole in humans are
ongoing (DNDi 2012). Another new product, Oxaborole SCYX-
7158, also for oral administration, is undergoing Phase I studies
(DNDi 2012b).
After several decades of scarce attention, the past few years have
seen a new impetus in the fight against HAT, due in good part
to an efficient co-ordination and collaboration between different
agencies, researchers, and national trypanosomiasis programmes,
the diminution of social upheavals, capacity building activities and
the free provision of diagnostic and reagents and medicines. The
situation has improved even in the few years since the protocol for
this Cochrane review was first published (2006): the total number
of HAT cases decreased 68% between 1995 and 2006 (Simarro
2008). Clinical trials of high methodological quality have been
completed since then (despite no significant reduction in the lo-
gistic challenges to be faced by trialists). So the practical implica-
tions of these latest trials go beyond their clinical results to also
include a framework for planning and executing trials in resource-
poor settings.
There are signs that the use of melarsoprol will decline. An anal-
ysis of pooled data from 11,668 patients from different coun-
tries showed that its effectiveness was lower than eflornithine
(Balasegaram 2009). In the absence of a direct randomized com-
parison betweenmelarsoprol, eflornithine and NECT, this is a rel-
evant finding due to the number of patients treated from several
different locations and a comprehensive analysis of the outcomes.
Also, although the choice of HAT therapy is often dictated by local
conditions of availability, active public-private partnerships have
allowed Gambiense HAT endemic countries to increase the use of
eflornithine and NECT, resulting in a decrease in the percentage
of melarsoprol treated patients from 86% in 2004 to 51% in 2008
(WHO 2009). Parasite resistance is less likely to develop with a
combination such as NECT, but a system of monitoring will be
needed to monitor the effectiveness of drug regimens over time.
It is imperative that studies on the reduction of the adverse ef-
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fects of currently used drugs, testing different regimens, and ex-
perimental and clinical studies on the development of new anti-
trypanosomal compounds, effective for both stages of the disease,
also continue taking place.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Choice of therapy for second stageGambienseHAT in the next few
years will continue to be dictated by local conditions of availability
and logistic difficulties, but it is envisioned that melarsoprol, with
its high level of adverse events, will be phased out in favour of
eflornithine and NECT. Parasite resistance to the drugs as well as
their effectiveness need to be carefully monitored in large cohort
studies.
Implications for research
It is essential that future research focus on the reduction of the
adverse effects of currently used drugs, tests on different regimens,
and experimental and clinical studies on the development of new
anti-trypanosomal compounds, effective for both stages of the
disease. Development of new diagnostic tools, both to improve
disease confirmation and to precisely determine the stage of the
disease, and to avoid the need for lumbar punctures performed
under unsafe conditions, is also necessary.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bisser 2007
Methods Open randomized equivalence trial
Generation of allocation sequence: “Block randomisation was prepared by the statistician
prior to the start of the study. A randomisation list was generated bymeans of the statistical
analysis system S.A.S 8.0 (SAS Institute, Cary, USA) ” - personal communication by the
author. and block randomization
Allocation concealment: “closed envelopes containing the treatment type and randomi-
sation number were prepared.” personal communication by the author
Blinding: not feasible
Inclusion of all randomized participants: ITT profile included, 93.8% participants com-
pleted treatment
Enrollment February-August 1998, follow up ends in 2000
Participants Number randomized: 278
Inclusion criteria: living in the study area; age > 15 years; parasitologically confirmed
second stage T. b. gambiense infection; no history of treatment for sleeping sickness
Exclusion criteria: pregnancy; Glasgow coma score < 8; active tuberculosis; potential
central nervous system (CNS) infection; severe organ disease
Diagnosis and follow-up methods: routine parasitological methods + cerebrospinal fluid
(CSF) cell count > 20 cells/µL
Interventions 1. Standard melarsoprol: 3.6 mg/kg/day for 3 days; 3 series with 7-day intervals; intra-
venous
2. Incremental melarsoprol: 10-day incremental melarsoprol (0.6 mg/kg day 1, 1.2 mg/
kg day 2, and 1.8 mg/kg at days 3 to 10; intravenous
3. Nifurtimox monotherapy: 5 mg/kg every 8 h for 14 days; oral
4. Melarsoprol-nifurtimox: consecutive 10-day melarsoprol-nifurtimox low-dose com-
bination; (2 days of melarsoprol alone at 0.6 mg/kg on day 1, 1.2 mg/kg on day 2,
and from days 3 to 10: melarsoprol at 1.2 mg/kg + nifurtimox 7.5 mg/kg every 8 h);
melarsoprol given intravenously; nifurtimox given orally
All participants pretreated with chloroquine for 3 days and with mebendazole
Prednisolone was given for treatment of encephalopathy
Outcomes 1. Relapse
2. Death after treatment
3. Cure at ≥24 months
4. Adverse events
Notes Location: Equator Province, Democratic Republic of Congo
Setting: hospital
Financial support: Belgian Ministry of Foreign Affairs, Directorate General for Devel-
opment Cooperation
Risk of bias
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Bisser 2007 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block computer-generated randomisation
was prepared before the study
Allocation concealment (selection bias) Low risk Sealed envelopes were used.
Blinding (performance bias and detection
bias)
All outcomes
High risk Regimens and modes of administration
were too different to allow blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT profile included, 93.8% participants
completed treatment
Burri 2000
Methods Randomized controlled equivalence trial
Generation of allocation sequence: randomization in blocks of 10
Allocation concealment: opaque sealed envelopes
Blinding: not feasible
Inclusion of all randomized participants: ITT profile included, 88.4 % participants
completed treatment
Duration: not mentioned
Participants Number randomized: 500
Inclusion criteria: age > 14 years; confirmed second-stage T. b. gambiense infection;
trypanosomes in CSF or > 5 WBC/µL in CSF.
Exclusion criteria: Glasgow coma score < 8; pregnancy; active tuberculosis
Diagnosis and follow-up methods: cerebrospinal fluid (CSF) examination, double cen-
trifugation
Interventions 1. Melarsoprol: 1.2 mg/kg on day 1, 2.4 mg/kg on day 2, 3.6 mg/kg on day 3, and 3.6
mg/kg on day 4; 3 series repeated at 7-day intervals; administered intravenously
2. Melarsoprol: 2.2 mg/kg/day per 10 days; administered intravenously
All participants were pretreated with chloroquine, mebendazole, multivitamins, and
paracetamol
Prednisolone was given to all participants at 1 mg/kg followed by decreasing doses
Outcomes 1. Cure rates at 24 h after treatment
2. Death
3. Relapse
4. Adverse events
Notes Location: Kwanza Norte Province, Angola
Setting: Trypanosomiasis Units
Funding: Swiss Agency for Development and Cooperation, partly World Health Orga-
nization: Division of Control of Tropical Diseases
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Burri 2000 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation in
blocks of tenwas done during pretreatment
Allocation concealment (selection bias) Low risk Non transparent, sealed envelopes were
used
Blinding (performance bias and detection
bias)
All outcomes
High risk Stated: “A masked trial design was not pos-
sible” because of substantial differences be-
tween the two treatment schedules
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT analysis included; 88.4% participants
analysed (not adequate)
Lejon 2003
Methods Open randomized equivalence trial
Generation of allocation sequence: block randomization
Allocation concealment: not specified
Blinding: Field team was blinded “for blocking procedures”
Inclusion of all randomized participants: ITT or per protocol profile not included, but
participants completed treatment
Duration: not mentioned
Participants Number randomized: 103
Inclusion criteria: age 2 to 59 years, presence of T. b. gambiense in blood, lymph nodes
or CSF, > 5 WBC/µL in CSF, ≤20 WBC/µL in CSF
Exclusion criteria: previous treatment for trypanosomiasis
Diagnosis and follow-up method: double centrifugation
Interventions 1. Pentamidine 4 mg/kg for 10 days
2. Melarsoprol (3 series of 3 injections at increasing doses)
Outcomes Relapse
Notes Location: Arua District, Uganda
Setting: not specified
Source of funding: Médecins Sans Frontières
Risk of bias
Bias Authors’ judgement Support for judgement
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Lejon 2003 (Continued)
Random sequence generation (selection
bias)
Low risk ’Block randomisation with uniform alloca-
tion..’
Allocation concealment (selection bias) Unclear risk Not mentioned
Blinding (performance bias and detection
bias)
All outcomes
Low risk The team on the field was blinded for
blocking procedures’
Incomplete outcome data (attrition bias)
All outcomes
Low risk nomention of ITTor per protocol analysis,
however 98 out of 103 participants com-
pleted treatment and were analysed
Na-Bangchang 2004
Methods Randomized controlled trial
Generation of allocation sequence: method not mentioned
Allocation concealment: not mentioned
Blinding: not mentioned
Inclusion of all randomized participants: ITT or per protocol profile not included, but
all 25 participants completed treatment
Duration: 2000 to 2002
Participants Number randomized: 25
Inclusion criteria: age 18 to 69 years; bodyweight 43 to 63 kg; parasitologically confirmed
second-stage T. b. gambiense infection
Exclusion criteria: pregnancy; lactating women; Glasgow coma scale < 8; chronicmedical
condition or critically ill
Diagnosis and follow-up methods: Miniature anion exchange centrifugation technique
and double centrifuge for detection of trypanosomes, cerebrospinal fluid (CSF) WBC
Interventions 1. Eflornithine, oral, 400 mg/kg/day (100 mg/kg every 6 h) for 14 days
2. Eflornithine, oral, 500 mg/kg/day (125 mg/kg every 6 h) for 14 days
All participants pretreated with chloroquine and albendazole
Outcomes 1. Cure rates
2. Death
3. Adverse events
Pharmacokinetics analysis
Notes Location: Daloa, Cote d’Ivoire
Setting: research centre
Source of funding: UNDP/World Bank/WHO Special Programme for Research and
Training in Tropical Diseases
Risk of bias
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Na-Bangchang 2004 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Patients were randomly allocated but
method not specified
Allocation concealment (selection bias) Unclear risk Not stated
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not mentioned in report
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data from all 25 patients were analysed
Pepin 1989a
Methods Prospective randomized trial
Generation of allocation sequence: not described
Allocation concealment: not specified
Blinding: not done
Inclusion of all randomized participants: ITT or per protocol profile not included, but
598 participants out of 620 enrolled, completed treatment (96.4%)
Study conducted between March 1984 and October 1988
Participants Number randomized: 620
Inclusion criteria: parasitologically confirmed cases of T. b. gambiense
Diagnosis and follow up methods: standard parasitological investigations and white cell
count (WCC)
Interventions 1. Melarsoprol: 3.6 mg/kg; 2 series of 3 injections if WCC < 20, 3 series of 3 injections
if WCC = 20 to 99, or 3 series of 4 injections if WCC ≥100; 1-week interval between
first and second series, and 2-week interval between second and third series
2. Melarsoprol + prednisolone: melarsoprol same as group 1; oral prednisolone as a single
daily dose of 1 mg/kg up to a maximum of 40 mg started on the day before first dose of
melarsoprol; given throughout first series, first interval, and second series of melarsoprol;
discontinued over 3 days after second series, resumed on the day before third series, and
discontinued over 3 days after the end of the third series
Pretreatment: mebendazole, chloroquine, and suramin 24 h before first melarsoprol dose
Outcomes 1. Relapse
2. Death
3. Encephalopathy and other adverse events
Notes Location: Nioki, Zaire (Democratic Republic of Congo)
Setting: hospital
Source of funding: Canadian International Development Agency
Risk of bias
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Pepin 1989a (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of randomization was not de-
scribed
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
High risk Not done
Incomplete outcome data (attrition bias)
All outcomes
Low risk 96.4% participants completed treatment
Pepin 2000
Methods Multicentre randomized controlled trial
Generation of allocation sequence: not specified
Allocation concealment: “There was no concealment of allocation as far as I can remem-
ber”, personal communication from the author
Blinding: not feasible
Inclusion of all randomized participants: 84% patients followed up to 1 year
Enrolment started July 1993, continued until February 1996, follow up completed in
April 1998
Participants Number randomized: 321
Inclusion criteria: parasitologically confirmed new patients and relapsing patients; likely
to complete follow up; age 3 to 77 years
Exclusion criteria (in new cases only): pregnancy; moribund patients
Diagnosis and follow-up methods: standard parasitological investigation and cere-
brospinal fluid (CSF) count
Interventions 1. Eflornithine: 400 mg/kg/day (100 mg/kg every 6 h), intravenous, for 7 days
2. Eflornithine: 400 mg/kg/day (100 mg/kg every 6 h), intravenous, for 14 days
Pretreatment or additional prednisolone: not mentioned
Outcomes 1. Treatment failure
2. Death
3. Adverse events
Notes Locations: Cote d’Ivoire, Congo, Democratic Republic of Congo, Uganda
Setting: 3 hospitals and one trypanosomiasis unit
Source of funding: UNDP/World Bank/WHO Special Programme for Research and
Training in Tropical Diseases
Risk of bias
Bias Authors’ judgement Support for judgement
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Pepin 2000 (Continued)
Random sequence generation (selection
bias)
Unclear risk ’Randomisation was carried out in each
hospital’ Methods not stated
Allocation concealment (selection bias) High risk Not mentioned or described in trial report
but the author was contacted and stated it
was not done
Blinding (performance bias and detection
bias)
All outcomes
High risk The authors state that blinding was not fea-
sible
Incomplete outcome data (attrition bias)
All outcomes
Low risk 84% patients were followed up to 1 year
(65% up to 2 years).
Pepin 2006
Methods Randomized controlled trial
Generation of allocation sequence: block randomization, method not specified
Allocation concealment: not done ( personal communication from the author)
Blinding: not feasible
Inclusion of all randomized participants: unclear how many participants completed
treatment
Enrolment started in April 1996 and was stopped in December 1998 for Arm C, en-
rolment in the other two arms continued until December 2001. Follow up data were
accumulated until January 2004
Participants Number randomized: 389
inclusion criteria: age > 13 years; parasitologically confirmed new cases of T. b. gambiense
trypanosomiasis; > 5 WBC/µL in CSF
Exclusion criteria: past history of treatment for trypanosomiasis; “moribund condition”;
resident outside area
Diagnosis and follow-up methods: standard parasitological investigation and cere-
brospinal fluid (CSF) count
Interventions 1. Melarsoprol: intravenous; 3.6 mg/kg/day; 3 series of 3 injections per day x 3 days,
repeat after 7-day interval; total duration 26 days
2. Melarsoprol: intravenous; 2.16 mg/kg/day once a day for 10 days
3. Melarsoprol: intravenous; graded dosing; 1.8/2.16/2.52/2.88/3.24/3.6 mg/kg/day; 3
series of 3 injections per day x 3 days, repeat after 7 days interval; total duration of 26
days
Pretreatment: all participants treated with pentamidine, chloroquine, and thiabendazole
All patients received oral prednisolone at 1 mg/kg
Outcomes 1. Cure rates
2. Relapse
3. Adverse events
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Pepin 2006 (Continued)
Notes Location: Nioki, Democratic Republic of Congo
Setting: hospital
Source of funding: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ’Block randomisation (blocks of ten)’
Allocation concealment (selection bias) High risk Not mentioned in article but author stated
it was not done
Blinding (performance bias and detection
bias)
All outcomes
High risk Not feasible
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk not mentioned in report
Priotto 2006
Methods Randomized, open-label, active control, parallel clinical trial
Generation of allocation sequence: randomization list in blocks of 18 was electronically
generated
Allocation concealment: randomization list and block size were blinded from the field
team. Sealed and numbered opaque envelopes were used
Blinding: not feasible due to the different administration modes of the drugs
inclusion of all randomized participants: ITT and per protocol analysis done, (>90%of
all participants randomized into the trial were included in the analysis)
Enrolment started in march 2001, suspended in November 2001 for ethical reasons
Participants Number randomized: 54
Inclusion criteria: confirmed second-stage T. b. gambiense infection with trypanosomes
detected in CSF, or trypanosomes detected in blood or lymph nodes with > 5 WBC/µL
in CSF
Exclusion criteria: pregnancy; residency outside area; body weight under 10 kg; history
of treatment for trypanosomiasis in the previous 2 years
Diagnosis and follow-up methods: double centrifugation of cerebrospinal fluid (CSF);
quantitative buffy coat (QBC) technique in blood
Interventions 1. Melarsoprol-nifurtimox: melarsoprol given intravenously, 1.8 mg/kg/day for 10 days;
nifurtimox given orally, 15 mg/kg/day, every 8 h for 10 days
2. Melarsoprol-eflornithine: melarsoprol given intravenously, 1.8 mg/kg/day for 10 days;
eflornithine given intravenously, 400 mg/kg/day, every 6 h for 7 days
3. Nifurtimox-eflornithine: respective doses as in groups 1 and 2
All participants were pretreated with albendazole, those with positive malaria diagnosis
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Priotto 2006 (Continued)
were treated with Fansidar (sulfadoxine and pyrimethamine), and those positive for
microfilariae were treated with ivermectin
Melarsoprol-treated participants received oral prednisolone (1 mg/kg/day for 5 days +
0.5 mg/kg/day) until treatment complete
Outcomes 1. Cure rates
2. Adverse events
Notes Location: Arua District, Uganda
Setting: trypanosomiasis centre
Source of funding: MSF and Embassy of France in Uganda
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Electronic block randomisation
Allocation concealment (selection bias) Low risk Sealed, numbered opaque envelopes
Blinding (performance bias and detection
bias)
All outcomes
High risk Not feasible - explicitly stated as such
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT and Per protocol analysis done, ade-
quate (>90% participants analysed)
Priotto 2009
Methods Multi-center, randomized, open label, non-inferiority trial
Generation of allocation sequence:randomization list in blocks of 10 was electronically
generated at the study headquarters
Allocation concealment: randomization list was concealed from the field team
Blinding: not feasible as different modes of administration
inclusion of all randomized participants: ITT and per protocol analysis done, (> 90% of
all participants randomized into the trial were included in the analysis)
Enrolment started August 2003 and completed June 2008
Participants Number randomized: 287
Inclusion criteria: over 15 yrs
Exclusion criteria: severe comorbidities, haemoglobin <5 g/dL, inability to complete 18
months follow up
Diagnosis and follow-up method: double centrifugation of CSF, QBC technique in
blood, latex IgM in CSF
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Priotto 2009 (Continued)
Interventions 1) Eflornithine, IV (slow infusion), 400 mg/kg/day (100 mg kg every 6 hrs) for 14 days
2) Eflornithine + nifurtimox; N = oral; E = IV (slow infusion); E = 400 mg/kg/day, every
12 hrs for 7 days; N = 15 mg/kg, every 8 hrs for 10 days
Malaria + patients were treated with artemether-lumefantrine
Outcomes Cure rates, death, relapse, adverse events.
Notes Locations:Nkayi (Republic ofCongo); Isangi,Dipumba,Katanda (DemocraticRepublic
of Congo)
Source of funding: MSF, DNDi
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk randomized through block randomization
in blocks of ten
Allocation concealment (selection bias) Low risk Adequate - numbered non-transparent en-
velopes were used
Blinding (performance bias and detection
bias)
All outcomes
High risk a blindeddesignwas not acceptable because
of differences in administration
Incomplete outcome data (attrition bias)
All outcomes
Low risk trial profile included and analysis per pro-
tocol, ITT and safety analysis done, 94.1%
participants included
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
APTED 1957 Not randomized
Balasegaram 2006 Retrospective analysis
Burri 1995 Not a comparative study
Butler 1957 Not a comparative study
Ceccaldi 1953 Not a comparative study
Chappuis 2005 Not a prospective trial
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(Continued)
Eozenou 1989 Not a comparative study
Janssens 1977 Not randomized
Khonde 1997 Not a comparative study
Moens 1984 Not a comparative study
Mpia 2002 Not a comparative study
Ogada 1973 Retrospective analysis
Pepin 1985 Retrospective analysis
Pepin 1989 Not a comparative study
Schmid 2005 Not a comparative study
Van Nieuwenhove 1985 Not a comparative study
Characteristics of ongoing studies [ordered by study ID]
DNDi 2012
Trial name or title Pivotal Study of Fexinidazole for Human African Trypanosomiasis in Stage 2
Methods Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assign-
ment, Masking: Single Blind
Participants 15 years old or more, male or female, with Karnofsky index>50, with parasitologically confirmed late-stage
African trypanosomiasis infection with T. b. gambiense in the blood and/or lymph and/or CSF, or WBC >20/
µL detected in the CSF to document stage 2 infection
Interventions Fexinidazole Compared to Nifurtimox-Eflornithine Combination Therapy
Outcomes success or failure at 18 months follow-up visit
Starting date September 2012
Contact information Antoine Tarral (DNDi), Victor Kande, HAT National Control Program in DRC
Notes
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DNDi 2012b
Trial name or title Human African Trypanosomiasis: First in Man Clinical Trial of a New Medicinal Product, the SCYX-7158
Methods Allocation: Randomized, Endpoint Classification: Safety Study, Masking: Double Blind (Subject, Caregiver,
Investigator, Outcomes Assessor)
Participants Male healthy volunteers 18 to 45 years of age, of sub-Saharan African origins
Interventions SCYX-7158 compared to placebo
Outcomes Safety, Tolerability, Pharmacokinetics and Pharmacodynamics
Starting date February 2012
Contact information Antoine Tarral (DNDi), Lionel Hovsepian (SGS Aster, Paris).
Notes
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D A T A A N D A N A L Y S E S
Comparison 1. Melarsoprol monotherapy: Drug A vs Drug B
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death during treatment 3 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 Melarsoprol: graded
(Angola regimen) vs fixed-dose
10 days
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Melarsoprol: standard (3.6
mg) vs graded (26 days)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.3 Melarsoprol: standard (3.
6 mg) vs incremental dose 10
days
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.4 Melarsoprol (standard 3.6
mg) vs nifurtimox (14 days)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.5 Melarsoprol: graded 26
days vs fixed 10 days
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Overall mortality 2 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2.1 Melarsoprol: graded
(Angola regimen) vs fixed-dose
10 days
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 Melarsoprol: standard (3.
6 mg) vs incremental dose 10
days
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Relapse during follow up 2 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3.1 Melarsoprol: graded
(Angola regimen) vs fixed-dose
10 days
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Melarsoprol: standard (3.
6 mg) vs incremental dose 10
days
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 2. Eflornithine monotherapy: Drug A vs Drug B
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death during treatment 2 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 Eflornithine: 7 days vs 14
days
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Eflornithine (oral): 400 vs
500 mg/kg/day
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Overall mortality 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
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2.1 Eflornithine (oral): 400 vs
500 mg/kg/day
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Relapse during follow up 2 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3.1 Eflornithine: 7 days vs 14
days
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Eflornithine (oral): 400 vs
500 mg/kg/day
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 3. Comparisons between single drugs: Drug A vs Drug B
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death during treatment 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 Melarsoprol (standard 3.6
mg) vs nifurtimox (14 days)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Nifurtimox (14 days) vs
melarsoprol (incremental 10
days)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Overall mortality 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2.1 Melarsoprol (standard 3.6
mg) vs nifurtimox (14 days)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 Nifurtimox (14 days) vs
melarsoprol (incremental 10
days)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Relapse during follow up 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3.1 Melarsoprol (standard 3.6
mg) vs nifurtimox (14 days)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Nifurtimox (14 days) vs
melarsoprol (incremental 10
days)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Relapse 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
4.1 Melarsoprol (standard
graded) vs pentamidine
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 4. Combination therapies: Drug A vs Drug B
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death due to HAT 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 Eflornithine-nifurtimox vs
melarsoprol-eflornithine
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Eflornithine-nifurtimox vs
melarsoprol-nifurtimox
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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1.3 Melarsoprol-eflornithine
vs melarsoprol-nifurtimox
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Death during treatment 3 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2.1Melarsoprol vs melarsoprol
+ prednisolone
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 Melarsoprol-nifurtimox
(10 days) vs melarsoprol
(standard 3.6 mg)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.3 Melarsoprol-nifurtimox vs
melarsoprol (incremental 10
days)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.4 Melarsoprol-nifurtimox vs
nifurtimox (14 days)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.5 Eflornithine (14 days) vs
eflornithine+nifurtimox
0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.6 Eflornithine-nifurtimox vs
melarsoprol-eflornithine
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.7 Eflornithine-nifurtimox vs
melarsoprol-nifurtimox
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.8 Melarsoprol-eflornithine
vs melarsoprol-nifurtimox
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Overall mortality 2 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
3.1 Melarsoprol-nifurtimox
(10 days) vs melarsoprol
(standard 3.6 mg)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Melarsoprol-nifurtimox vs
melarsoprol (incremental 10
days)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.3 Melarsoprol-nifurtimox vs
nifurtimox (14 days)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.4 Eflornithine (14 days) vs
eflornithine+nifurtimox
0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.5 Eflornithine-nifurtimox vs
melarsoprol-eflornithine
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.6 Eflornithine-nifurtimox vs
melarsoprol-nifurtimox
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.7 Melarsoprol-eflornithine
vs melarsoprol-nifurtimox
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Relapse during follow up 3 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
4.1Melarsoprol vs melarsoprol
+ prednisolone
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 Melarsoprol-nifurtimox
(10 days) vs melarsoprol
(standard 3.6 mg)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.3 Melarsoprol-nifurtimox vs
melarsoprol (incremental 10
days)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.4 Melarsoprol-nifurtimox vs
nifurtimox (14 days)
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.5 Eflornithine (14 days) vs
eflornithine+nifurtimox
0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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4.6 Eflornithine-nifurtimox vs
melarsoprol-eflornithine
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.7 Eflornithine-nifurtimox vs
melarsoprol-nifurtimox
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.8 Melarsoprol-eflornithine
vs melarsoprol-nifurtimox
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
A D D I T I O N A L T A B L E S
Table 1. Pre-treatment and additional treatment of HAT patients
Trial Pre-treatment Corticosteroids
Bisser 2007 • Chloroquine 3 days
• Mebendazole
Not systematically given, only for treatment of en-
cephalopathy
Burri 2000 • Chloroquine
• Mebendazole
• Multivitamins
• Paracetamol
Prednisolone (1 mg/kg + decreasing doses)
Lejon 2003 Not mentioned Not mentioned
Na-Bangchang 2004 • Chloroquine
• Albendazole
Not mentioned
Pepin 1989 • Mebendazole
• Chloroquine
• Suramin (24 h before first melarsoprol dose)
Not applicable
Pepin 2000 Not mentioned Not mentioned
Pepin 2006 • Pentamidine
• Chloroquine
• Thiabendazole
Oral prednisolone (1 mg/kg)
Priotto 2006 • Albendazole
• Malaria diagnosis + treated with Fansidar
(sulfadoxine and pyrimethamine)
• Microfilariae + treated with ivermectin
Melarsoprol-treated patients received oral pred-
nisolone (1 mg/kg/day for 5 days + 0.5 mg/kg/day)
until treatment completed
Priotto 2009 • Malaria + were treated with artemether-
lumefantrine
Not applicable
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Table 2. Adverse events
Comparison (Drug A
vs Drug B)
Trial n/Na Adverse event
Drug A Drug B
Melarsoprol monotherapy
Melar-
soprol: graded (Angolan)
vs fixed 10 days
Burri 2000 14/250 14/250 Encephalopathy
17/250 18/250 Diarrhoea
15/250 39/250 Skin reactions
Melarsoprol: standard 3.
6 mg vs graded 26 days
Pepin 2006 7/149 7/70 Seizures
10/149 3/70 Confusion
1/149 0/70 Skin reactions
Melarsoprol: standard 3.
6 mg vs incremental 10
days
Bisser 2007 4/69 5/70 Encephalopathy
7/69 5/70 Diarrhoea
14/69 11/70 Nausea and vomiting
19/69 13/70 Infection (phlebitis)
Standard melarsoprol 3.
6 mg vs fixed melarso-
prol 10 days
Pepin 2006 10/149 6/170 Confusion
7/149 4/170 Seizures
1/149 6/170 Skin reactions
Graded melarsoprol 26
days vs fixed melarsoprol
10 days
Pepin 2006 3/70 6/170 Confusion
7/70 4/170 Seizures
0/70 6/170 Skin reactions
Eflornithine monotherapy
Eflornithine 7 days vs 14
days
Pepin 2000 7/158 10/163 Seizures
13/158 26/163 Diarrhoea
7/158 13/163 Nausea and vomiting
5/158 24/163 Infection
Oral eflornithine 500 vs
400 mg
Na-Bangchang 2004 7/13 7/12 Diarrhoea
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Table 2. Adverse events (Continued)
9/13 8/12 Anaemia
8/13 8/12 Leukopenia
Comparisons between single drugs
Standard melarsoprol 3.
6 mg vs nifurtimox 14
days
Bisser 2007 4/69 1/70 Encephalopathy
7/69 10/70 Diarrhoea
14/69 17/70 Nausea and vomiting
19/69 0/70 Infection (phlebitis)
Melarsoprol incremental
10 days vs nifurtimox 14
days
Bisser 2007 5/70 1/70 Encephalopathy
5/70 10/70 Diarrhoea
11/70 17/70 Nausea and vomiting
13/70 0/70 Infection (phlebitis)
Standard (graded)
melarsoprol vs pentami-
dine
Lejon 2003 None recorded None recorded -
Combination therapies
Melarsoprol vs melarso-
prol+prednisolone
Pepin 1989a 35/308 12/290 Encephalopathy
4/308 3/290 Skin reactions
8/308 8/290 Infections
Standard melarsoprol 3.
6 mg vs melarsoprol-ni-
furtimox 10 days
Bisser 2007 4/69 2/69 Encephalopathy
7/69 7/69 Diarrhoea
14/69 12/69 Nausea and vomiting
19/69 6/69 Infection (phlebitis)
Melarsoprol incremental
10 days vs melarsoprol-
nifurtimox
Bisser 2007 5/70 2/69 Encephalopathy
5/70 7/69 Diarrhoea
11/70 12/69 Nausea and vomiting
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Table 2. Adverse events (Continued)
13/70 6/69 infection (phlebitis)
Nifurtimox 14 days vs
melarsoprol-nifurtimox
Bisser 2007 1/70 2/69 Encephalopathy
10/70 7/69 Diarrhoea
17/70 12/69 Nausea and vomiting
0/70 6/69 infection (phlebitis)
Eflornithine vs
eflornithine-nifurtimox
Priotto 2009 13/143 18/143 Seizures
41/143 9/143 Diarrhoea
29/143 69/143 Nausea and vomiting
1/143 2/143 Anaemia
10/143 2/143 Neutropenia
25/143 14/143 Infection
20/143 4/143 Skin reactions
Eflornithine-ni-
furtimox vs melarsoprol-
eflornithine
Priotto 2006 4/17 2/19 Seizures
4/17 8/19 Diarrhoea
1/17 4/19 Nausea and vomiting
0/17 0/19 Skin reactions
3/17 1/18 Neutropenia
Eflornithine-ni-
furtimox vs melarsoprol-
nifurtimox
Priotto 2006 4/17 4/18 Seizures
4/17 3/18 Diarrhoea
1/17 1/18 Nausea and vomiting
3/17 0/18 Neutropenia
0/17 1/18 Skin reactions
Melarsoprol-
eflornithine vs melarso-
prol-nifurtimox
Priotto 2006 2/19 4/18 Seizures
8/19 3/18 Diarrhoea
4/19 1/18 Nausea and vomiting
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Table 2. Adverse events (Continued)
1/18 0/18 Neutropenia
0/18 1/18 Skin reactions
an/N: number of participants with adverse event/total number of participants.
WH A T ’ S N E W
Last assessed as up-to-date: 10 January 2013.
Date Event Description
18 June 2013 New citation required but conclusions have not
changed
Updated search. No new included studies.
25 February 2013 New search has been performed Updated the search for trials, added two ongoing trials,
changed search dates in the review, added a few ’Addi-
tional References’, slightly modified the Discussion
C O N T R I B U T I O N S O F A U T H O R S
VLutje developed and drafted the protocol; J Seixas provided comments and reviewed it. All three authors contributed to data extraction,
A Kennedy assessed risk of bias, V Lutje run the literature searches, entered data into Review Manager 5 and prepared the first draft of
the review, all three authors contributed to revisions and to the final version.
D E C L A R A T I O N S O F I N T E R E S T
None known.
S O U R C E S O F S U P P O R T
Internal sources
• Liverpool School of Tropical Medicine, UK.
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External sources
• Department for International Development (DFID), UK.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The title was changed to “Chemotherapy for second-stage Human African trypanosomiasis”.
A. Kennedy joined the review team after the protocol was published.
We deviated from the protocol as follows: updated and modified the Background section; reduced the number and slightly modified
the outcome measures; modified the list of adverse events to include skin reactions and infections.
As the trials included different treatments, we did not perform meta-analysis, subgroup analysis and investigation of heterogeneity, or
sensitivity analysis.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Trypanosoma brucei gambiense; Antiprotozoal Agents [adverse effects; ∗therapeutic use]; Drug Therapy, Combination [methods];
Eflornithine [therapeutic use];Melarsoprol [therapeutic use]; Nifurtimox [therapeutic use]; Pentamidine [therapeutic use]; Prednisolone
[therapeutic use]; Randomized Controlled Trials as Topic; Recurrence; Trypanosomiasis, African [∗drug therapy]
MeSH check words
Animals; Humans
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